FUJIFILM Pharmaceuticals  U.S.A. , Inc.   Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
 
Confidential and Proprietary  Page 1 of 43   
 
 
Open Label, Randomized , Controlled Phase 2 Proof -of-Concept 
Study of the Use of Favipiravir Compared to Standard of Care  
in Hospitalized Subjects with COVID -19 
 
 
 
 
PROTOCOL NUMBER:  FAVI -COV-US201 
 
IND NUMBER:   148286 
 
 
INVESTIGATIONAL   favipiravir 
PRODUCT:   
 PROTOCOL VERSION Version 6.0 
/DATE:   15July2020 
 
  
SPONSORED BY:   FUJIFILM Pharmaceuticals U.S.A. , Inc. 
   One Broadway, Cambridge , MA 02142 
   USA 
   
CONTACT  Sponsor’s Representative:  
INFORMATION:  Moriyoshi Maeda  
 Email: mmaeda@fujifilm.com 
 
 Acting Chief Medical Officer  
 Carol Epstein, MD  
 Email: carol@biologics.com  
 Mobile phone: +1 617-548-2221 
  
Confidentiality Statement  
This document is the confidential and proprietary information of FUJIFILM Pharmaceuticals U .S.A., 
Inc. (FPHU) The confidential information in this document is provided to you as a Potential Investigator 
or consultant for review by you, your staff and the a pplicable Institutional Review Board. You may 
disclose the contents of this document only to study personnel under your supervision or to your 
Institutional Review Board  who need to know the purpose of this clinical trial for approval decisions. 
Your acceptance of this document constitutes agreement that you will not disclose the information 
contained herein to others without written authorization from FPHU.  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 2 of 43   
     
FUJIFILM PHARMACEUTICALS  U.S.A. , INC. 
PROTOCOL FAVI -COV -US201 APPROVAL  
 
Version 6.0, 15July2020 
   
(SIGNATURE S ON FILE AT FPHU ) 
        _______________________________   ___________________ 
Mikihiko Kato       Date (MM/DD/YYYY)  
FUJIFILM Pharmaceutical U.S.A ., Inc.        
    _______________________________   ___________________ 
Carol Epstein, M.D.       Date (MM/DD/YYYY)  
Acting Chief Medical Officer        
FUJIFILM Pharmaceutical U.S.A ., Inc.  
    _______________________________   ___________________  
John Balser, Ph.D.      Date (MM/DD/YYYY)  
President and Chief Biostatistician  
Veristat  
      
  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 3 of 43  PROTOCOL SIGNATURE PAGE  
 
  Protocol Title:  Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study 
of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects with COVID -19 
 
Protocol Number: FAVI -COV-US201 
 
 Protocol Version/Date:  Version 6.0 
15July2020 
  
Sponsor Name:  FUJIFILM Pharmaceuticals U.S.A. , Inc. 
  One Broadway, Cambridge , MA 02142 
  USA 
 
 
  
Declaration of Investigator  
 I confirm that I have read the above -mentioned protocol and its attachments. I agree to conduct 
the described trial in compliance with all stipulations of the protocol, regulations and ICH E6 
Guideline for Good Clinical Practice (GCP).  
 
  
 
 Principal Investigator Name:  __________________________________________   Principal Investigator Signature:  _______________________________________   Date:   ___________________ 
           Date (MM/DD/YYYY)  
 
    
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 4 of 43   
TABLE OF CONTE NTS 
1 SYNOPSIS  ...............................................................................................................................8  
2 INTRODUCTION ................................................................................................................14  
2.1 Background Information ............................................................................................14  
2.2 Preclinical and In Vitro Experiences  ........................................................................15  
2.3 Clinical Experience .....................................................................................................15  
2.4 In Vitro Therapeutic Levels  .......................................................................................16  
2.5 Phase 1 Study Steady State Exposure  .......................................................................16  
2.6 Rationale for 14-day Dosing Regimen .......................................................................18  
2.7 Rationale for the Current Study  ................................................................................18  
3 DESIGN  .................................................................................................................................19  
4 OBJECTIVES  .......................................................................................................................19  
4.1 Primary Objectiv e .......................................................................................................19  
4.2 Secondary Objectives  ..................................................................................................19  
5 SUBJECT POPULATION  ...................................................................................................20  
5.1 Inclusion Criteria  ........................................................................................................20  
5.2 Exclusion Criteria  .......................................................................................................20  
5.3 Removal of Subjects from Treatment  .......................................................................21  
5.4 Individual Stopping Rule  ............................................................................................22  
6 STUDY TREATMENT - FAVIPIRAVIR  ..........................................................................22  
6.1 Study Drug  ...................................................................................................................22  
6.2 Standard Dose  .............................................................................................................22  
6.3 Administration of Favipiravir ....................................................................................22  
6.3.1  Outpatient Favipiravir Dosing ..........................................................................23  
6.4 Drug Accountability  ....................................................................................................23  
6.5 Treatment Compliance  ...............................................................................................23  
6.6 Treatment Precautions  ...............................................................................................23  
6.7 Proh ibited Concomitant Therapy  ..............................................................................23  
7 STUDY PROCEDURES  ......................................................................................................24  
7.1 Day 1 (PRE- DOSE)  .....................................................................................................24  
7.2 Day 1 (F IRST DOSE AND POST -DOSE)  ................................................................25  
7.3 Days 2 and 14 ...............................................................................................................26  
7.4 Days 3, 8 and 11 ...........................................................................................................26  
7.5 Days 15 and 29 (Follow-up) or Early Termination ..................................................27  
7.6 Days 45 and 60 (Additional Safety Follow- up) .........................................................27  
7.7 Day of Discharge from Hospital.................................................................................28  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 5 of 43  8 EFFICACY, PHARMACOKI NETICS AND SAFETY AS SESSMENTS  ......................28  
8.1 Efficacy Assessments  ...................................................................................................28  
8.2 Required Resistance Testing  ......................................................................................29  
8.3 Pharmacokinetics/Pharmacodynamics Assessments  ...............................................29  
8.4 Safety Assessments ......................................................................................................29  
8.4.1  Adverse Events ..................................................................................................30  
8.4.2  Defini tion of an Adverse Event.........................................................................30  
8.4.3  Evaluating and Reporting of Adverse Events ...................................................31  
8.4.4  Serious Adverse Events (SAEs) ........................................................................32  
8.4.5  Definition of Serious Adverse Events ...............................................................32  
8.4.6  SAE Reporting Requirements to the Sponsor ...................................................32  
8.5 Suspected Unexpected Serious Adverse Reactions (SUSARs)  ................................33  
8.5.1  Reporting SUSARs to the FDA: IND Safety Reports  ......................................33  
8.6 Clinical Laboratory Abnormalities and Other Ab normal Assessments  ................34  
8.7 Handling of Overdose  .................................................................................................34  
9 STATISTICAL METHODS  ................................................................................................34  
9.1 General Considerations ..............................................................................................34  
9.2 Sample size justification  .............................................................................................35  
9.3 Demographic and Baseline Characteristics  ..............................................................35  
9.4 Analysis Populations ...................................................................................................35  
9.5 Stratification, Subgroup Analysis and Pooled Analysis ..........................................36  
9.6 Efficacy Endpoint Analysis ........................................................................................36  
9.7 Safety Analysis .............................................................................................................37  
10 RECORDING AND COLLECTION OF DATA ...............................................................37  
10.1  Case Report Form  .......................................................................................................37  
10.2  Study Files and Subject Source Documents  .............................................................38  
10.3  Monitoring  ...................................................................................................................38  
10.4  Audit  .............................................................................................................................38  
10.5  Retention of Data .........................................................................................................39  
11 ETHICS  .................................................................................................................................39  
11.1  Ethics Committee  ........................................................................................................39  
11.2  Subject  Information and Consent  .............................................................................39  
12 GENERAL CONSIDERATIONS  .......................................................................................39  
12.1  Discontinuation of the Study  ......................................................................................39  
12.2  Use of Information and Publication ..........................................................................39  
13 SCHEDULE OF ASSESSME NTS  ......................................................................................41  
Appendix A: Subject Status Scales  .....................................................................................43  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 6 of 43   
List of Abbreviations  
AE Adverse event  
ALT  Alanine aminotransferase  
AO Aldehyde oxidase  
AST  Aspartate aminotransferase  
BID “bis in dies” / Twice a day  
BMI  Body mass index  
CAPD  Continuous ambulatory peritoneal dialysis  
CI Confidence interval(s)  
COVID -19  Corona Virus Disease 2019  
CRP  C-reactive Protein  
EC 50 Half maximal effective concentration  
ECMO  Extracorporeal membrane oxygenation  
eCRF  Electronic case report form  
EDC  Electronic data capture  
FDA  Food and Drug Administration  
FiO2  Fraction of inspired oxygen  
FPHU  FUJIFILM Pharmaceuticals U.S.A. , Inc. 
GCP  Good Clinical Practice  
HIV Human immunodeficiency virus  
IB Investigator Brochure  
ICH International Conference on  Harmonization  
IEC Institutional ethics committee  
IRB Institutional review board  
ITT Intent -to-treat 
IUD Intra -uterine device  
MedDRA  Medical dictionary for regulatory activities  
MERS -CoV  Middle East respiratory syndrome coronavirus  
MITT  Modified intent -to-treat 
NEWS 2 National early warning score  2 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 7 of 43  NO Nitrous Oxide  
PaO2  Partial pressure of oxygen  
PCR  Polymerase chain reaction  
PI Principal Investigator  
PK Pharmacokinetic(s)  
PP Per-protocol  
RNA  Ribo -nucleic acid  
RT-PCR  Reverse transcriptase polymerase chain reaction  
SAE  Serious adverse event  
SARS -CoV -2 Severe acute respiratory syndrome corona virus 2  
SD Standard deviation  
SOC  Standard of care  
SpO2 Peripheral capillary oxygen saturation  
SUSAR  Suspected unexpected serious adverse reaction  
TCID 50 Median tissue culture infectious dose  
TEAE  Treatment -emergent adverse event  
TTCR  Time to clinical recovery  
WHO  World Health Organization  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 8 of 43  1 SYNOPSIS  
Title  Open Label, Randomized, Controlled, Phase 2 Proof-of-Concept Study 
of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects 
with COVID -19 
Design  This is an open label, randomized, controlled, multicenter Phase 2 proof-
of-concept study of favipiravir in hospitalized subjects with COVID -19.  
Subjects will be randomized within their study site and  stratified by the 
severity of their disease to receive either favipiravir + standard of care (SOC) or SOC alone.  
The dose regimen will be 1800 mg favipiravir BID plus SOC or SOC alone on Day 1 followed by 1000 mg BID favipiravir (800 mg BID for 
subjects with Child -Pugh A liver impairment) plus SOC or SOC for the 
next 13 days. 
The study will have 14 days of treatment and 46 days of follow -up. 
Objectives  Primary Objective  
To determine the effect of favipiravir +  SOC v. SOC on viral clearance.  
Secondary Objectives  
1. To determine the clinical benefit of administering favipiravir plus 
SOC compared to SOC alone [ assessed using a study -specific 6 -
point ordinal scale adapted from the  WHO Master Protocol (V2.0 
24FEB20) COVID -19 7 -point ordinal scale ] on Day 15 in adult 
patients hospitalized with COVID -19. 
2. To determine if the treatment effect on the 6 -point ordinal scale, on 
Day 15, is reasonably likely to reflect clinical benefit, such that it 
can be used as the primary clinical outcome endpoint in a similar 
study that is double -blinded, by assessment of the relationship of the 
scale to changes in clinical and symptom outcomes, including time 
to clinical recovery, occurrence of fever, cough, dyspnea, reduction in oxygen r equirements, and other measures . 
3. To explore the clinical effect of favipiravir + SOC v. SOC as 
measured by the National Early Warning Score 2 ( NEWS 2) system.  
4. To determine the safety of favipiravir plus SOC compared to SOC alone, in this population. 
5. To explore the PK of this dose regimen of favipiravir in this patient population. 
Endpoints  Primary Endpoint:  
Time to viral clearance.  
Secondary Endpoints:  
1. Status of Clinical recovery as measured by the study -specific 6-point 
ordinal scale at Day 15.  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 9 of 43  2. Time to Clinical Recovery (TTCR) as assessed up to 2 9 days and 
defined as:  
a. The time (in hours) from initiation of study treatment ( favipiravir 
+ SOC or SOC alone ) until normalization of fever, respiratory 
rate, and oxygen saturation, and alleviation of cough, sustained 
for at least 72 hours ; or discharge. 
b. Normalization and alleviation criteria are defined as: 
i. Fever  – ≤ 37.2 °C oral, 
ii. Respiratory rate – ≤  24/minute on room air, 
iii. Oxygen saturation – SpO2  > 94% on room air, 
iv. Cough – mild or absent on a patient report ed scale of severe, 
moderate, mild, absent. 
3. Clinical effect as measured by the National Early Warning Score 2 (NEWS2) system.  
4. All-cause mortality as assessed  daily up to 29 days and at final 
follow up on Day 60. 
5. Frequency of respiratory progression as assessed up to 2 9 days (daily 
and per SOC at each site) and defined as: a. SpO2 ≤  94% on room air or PaO2/FiO2 < 300mmHg, and  
b. requirement for supplemental oxygen, or 
c. more advanced ventilator support. 
6. Time to defervescence (in those with fever at enrollment) as assessed daily up to 29 days  and at Day 60 (if possible). 
7. Time to cough reported as mild or absent (in those with cough at 
enrollment rated severe or moderate) as assessed daily up to 29 days 
and on Day 60. 
8. Time to dyspnea reported as mild or absent (on a scale of severe, 
moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate) as assessed daily up to 29 days and on Day 60 
(if possible). 
9. Frequency of requirement for supplemental  oxygen or non-invasive 
ventilation as assessed daily up to 29 days  and on Day 60. 
10. Time to SARS -CoV- 2 RT -PCR negative in upper respiratory tract 
specimen as assessed up to 2 9 days.  
11. Change in SARS -CoV- 2 viral load in upper respiratory tract 
specimen as assessed by area under viral load curve as assessed up to 29 days.  
12. Frequency  of requirement for mechanical ventilation as assessed up 
daily  to 29 days  and at Day 60  
13. Safety of favipiravir + SOC v. SOC alone as assessed daily up to 
29 days  and at Day 60. 
14. C-react ive protein (CRP) over time . 
15. Population PK analysis of favipiravir with assessment of maximum plasma concentration (C
max), minimum plasma concentration (C min), 
and AUC (0-24h) on Days 1, 2, 8 and 14. 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 10 of 43  Study Sites  Approximately 8 sites in the U.S .A. 
Planned 
Enrollment  Approximately 50 subjects; randomized 1:1 
Study Population  Adults who are hospitalized for treatment of confirmed COVID -19 
Subject Entry Criteria  Inclusion Criteria (all questions must be answered YES)  
1. Adults (18 to 80 years old): 
a. within 72 hours of their hospitalization  for infection with 
SARS -CoV-2, AND, 
b. within 72 hours of the latest PCR positive result  and within 
7 days of the 1st PCR positive result  for SARS -CoV-2. (The 
latest PCR could be the only PCR result .), AND, 
c. within 10 days of onset of any COVID-19 symptoms.  
2. Subject or their legal representative understands the requirements of 
the study and provides written informed consent prior to 
undergoing any treatment -related procedures.  
3. If male, subject must:  
a. Be sterile (e.g. , have had a vasectomy at least 6 months prior to 
Day 1 dosing), OR, 
b. Agree not to donate sperm during the study and for seven days following the last dose of study medication, AND, 
c. Agree to strictly adhere to the following contraceptive 
measures during the study and for  seven days following the last 
dose of study medication: 
i. Abstain from sexual intercourse. 
ii. Use a condom during sexual intercourse with a female of child -bearing  
potential. In addition, the female partner 
must use another form of  contraception (e.g. intrauterine 
device [IUD], diaphragm with spermicide, oral  
contraceptives, injectable progesterone, or subdermal 
implants).  
4. If female, subject must:  
a. Be unable to bear children (have not had a period for ≥  12 
consecutive months, have  had her uterus or  ovaries removed, 
or have had a tubal ligation), OR, 
b. Must ensure that their male partner is incapable of fathering a child (e.g., has had a vasectomy at least  6 months prior to study 
entry), OR, 
c. If she is of childbearing potential will strictly adhere to the following contraceptive  
measures during the study and for 
seven days following the last dose of study medication: 
i. Abstain from sexual intercourse, OR, 
ii. Must ensure that her male partner agrees to use a 
condom during sexual intercours e and a gree to use an  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 11 of 43  approved method of contraception (e.g., IUD, 
diaphragm with  spermicide, oral contraceptives, 
injectable progesterone, or subdermal implants) . 
d. Agrees to stop breast -feeding prior to first dose of study drug 
and through seven days after completing therapy. 
e. Has a negative pregnancy test at screening.  
f. Has not had unprotected sexual intercourse within the past 
month. 
Exclusion Criteria (all questions must be answered NO)  
1. Subject has a concomitant bacterial respiratory infection unless 
cleared by the Sponsor 
NOTE:  Subjects on empirical antibiotic 
treatment for possible but unproven bacterial 
pneumonia, but who are positive for SARS -
CoV-2, are allowed in the study. 
2. Subject has a history of abnormalities of uric acid metabolism 
unless cleared by the Sponsor. 
3. Subject has a history of hypersensitivity to an anti -viral nucleoside -
analog drug targeting a viral RNA polymerase. 
4. Subject is using adrenocorticosteroids (except topical or inhaled 
preparations or oral preparations equivalent to or less than 10 mg of 
oral prednisone) or immunosuppressive  or immunomodulatory  
drugs (e.g., immunosuppressants, anticancer drugs , interleukins, 
interleukin antagonists or interleukin receptor blockers ). 
NOTE: Treatment of study participants 
following institutional COVID -19 treatment 
policies or guidelines, including the use of immunomodul atory medications, is permitted . 
Per the conclusions of T he Randomised 
Evaluation of COVID -19 therapy 
(RECOVERY) trial 
(https://www.med rxiv.org/content/10.1101/202
0.06.22.20137273v1; accessed 13Jul2020), dexamethasone 6 mg daily (PO or IV) for 10 days is permitted . This excludes treatment with 
agents that have the potential for direct antiviral activity, including convalescent plasma and NO, and co -enrolment into other 
clinical studies that evaluate investigational agents for COVID-19. 
5. Subject has a serious chronic disease (e.g ., human 
immunodeficiency virus (HIV), cancer requiring chemotherapy 
within the preceding 6 months, moderate or se vere hepatic 
insufficiency and/or unstable renal, cardiac, pulmonary, neurologic, 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 12 of 43  vascular, or endocrinologic disease states requiring medication dose 
adjustments within the last 30  days).  
6. Has previously received favipiravir within  the past 30 days. 
7. Has re nal insufficiency requiring hemodialysis or continuous 
ambulatory peritoneal dialysis (CAPD)  or glomerular filtration rate 
of less than 20 mL/min. 
8. Has liver impairment greater than Child -Pugh A . (NOTE: Child -
Pugh A subjects will have the maintenance dose decreased to 800 
mg BID).  
9. Has a history of alcohol or drug abuse in the previous 6 months. 
10. Has a psychiatric disease that is not well controlled where 
controlled is defined as: stable on a regimen for more than one year. 
11. Has taken another investigational drug within the past 30 days. 
12. Is on another antiviral or is participating in a clinical trial for the 
treatment of COVID -19. 
13. Subject is on ventilator at the time of study entry . 
14. Is deemed by the Investigator to be ineligible for any reason.  
Treatment Regimen for Favipiravir 
(Standard dose)  • Favipiravir tablets will be administered orally. If necessary, a slurry 
may be administered by nasogastric tube.  
• The regimen begins with loading doses of 1800 mg BID on Day 1 
(the first 24 hours of treatment at t =0 and t = 12 hours) then 
maintenance dosing of 1000 mg BID from Day 2 (beginning 24 hours 
after the start of therapy).  
• Patients with Child -Pugh liver impairment of grade A will have their 
maintenance dose decreased to 800 mg BID. 
• The total duration of treatment is expected to be 14 days. 
• The dose regimen may be altered, after consultation between the 
treating physician and the Sponsor, depending on the clinical 
condition of the patient. 
Duration of Study Participation Subjects will participate in the study for up to 60 days: 14 days treatment 
(or as discussed with the Sponsor) and  46 days follow up. 
Statistical Methods  • This study is intended to be exploratory. Based upon available data, a 
two-arm study of approximately 50 total subjects will be sufficient to 
provide reasonable assurance that the endpoints chosen for a 
confirmatory trial will elucidate treatment differenc es between 
favipiravir and a control. Statistical significance testing will be used 
to assess the relative strength of evidence of the primary and 
secondary endpoints . 
• Randomization will be stratified by:  
• Site 
• Severity of illness at enrollment:  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 13 of 43  o Critical disease:  
 Requires supplemental oxygen delivered by non-
rebreather mask or high -flow cannula, OR 
 Use of invasive or non-invasive ventilation, OR 
 Requiring treatment in an intensive care unit, use of 
vasopressors, extracorporeal life support. 
o Severe disease:  
 Evidence of pneumonia on chest x -ray or CT scan, or 
chest auscultation (rales, crackles), OR  
 SpO2 ≤  93% on room air OR PaO2/FiO2 <  300 mmHg, 
OR 
 Requires supplemental oxygen by nasal canula, simple 
face mask, or other similar oxygen delivery device. 
o Mild -moderate disease: SpO2  > 94% and respiratory rate <  24 
breaths/min without supplemental oxygen 
• There is no planned interim analysis . 
Individual Stopping Rule  A subject should  be removed from favipiravir treatment  if one of the 
following criteria is met: 
• AST or ALT > 8 × ULN  
• ALT or AST > 3 × ULN AND total bilirubin > 2  × ULN  
• AST or ALT > 3 × ULN AND patient has right upper quadrant pain 
or eosinophilia 
• Uric acid > 20 mg/dL  
Study Measurements: Efficacy,  Safety 
and PK  Primary Efficacy Measurement:  
Presence of virus in the nasopharyngeal and oropharyngeal samples taken on D ays 1, 3, 8, 11, 15 and 29 ( if hospitalized and when able to return to 
clinic after discharge). 
Swabs will also be obtained on day of discharge 
from hospital if discharge occurs before Day 15. 
Secondary Measurements (Efficacy, Safety and PK) : 
1. Clinical improvement of hospitalized subjects with COVID -19 
receiving either favipiravir + SOC or SOC alone as defined by the 
following study- specific 6-point ordinal scale at Day 15 
a. Not hospitalized  
b. Hospitalized, not requiring supplemental oxygen 
c. Hospitalized, requiring supplemental oxygen 
d. Hospitalized, on non- invasive ventilation or high flow oxygen 
devices  
e. Hospitalized, on invasive mechanical ventilation or ECMO  
f. Death  
2. Status on the 6-point ordinal scale assessed daily while 
hospitalized and at each outpatient visit until Day 60. 
3. NEWS 2 assessed daily while hospitalized and at each outpatient visit 
until Day 60 . 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 14 of 43  4. Patient status assessed daily  while hospitalized and at each outpatient 
visit until Day 60  via S tudy-specific S ymptom Status and the ECOG 
Performance Status questionnaires (see Appendix A). 
5. Duration of supplemental oxygen (if applicable).  
6. Duration of mechanical ventilation (if  applicable).  
7. Duration of hospitalization.  
8. Date and cause of death (if  applicable).  
9. Safety as assessed by:  
a. Observed and reported adverse events.  
b. Hematology and chemistry laboratories on Days 1; 3, 8, 11, 15 
and 29 (if hospitalized and when able to return to clinic after 
discharge)  
c. Physical Examination at s creening, Day 15 and Day 29. 
d. Vital signs  daily while hospitalized and at each outpatient visit 
until Day 60 
10. Qualitative and quantitativ e PCR and TCID50 in nasopharyngeal 
and oropharyngeal swabs on D ays 1 (pre-dose) ; 3, 8, 11, 15 and 29 
(if hospitalized and when able to return to clinic after discharge) . 
Swabs will also be obtained on day of discharge from hospital if 
discharge occurs before Day 15.  
11. Blood for determination of antibodies to SARS -CoV- 2 will be 
obtained on Days 1, 15 and 29 (if hospitalized and  when able to 
return to clinic after discharge) . 
12. Blood 6.0 ml  for PK  in patients randomized to favipiravir is obtained 
pre-dose (within  30 minutes prior to dosing) and post-dose (45 to 75 
minutes following dosing) on Day 1 and trough levels on Day s 2, 8  
and the last day of favipiravir treatment (Day 14 unless subject 
leaves the study before completing treatment)  and peak levels on 
Days 3 and 11 post-dosing. 
To gather these measurements  – subjects will undergo 9 planned 
venipunctures  
 
2 INTRODUCTION 
2.1 Background Information 
Favipiravir, a small molecule, is a novel anti- viral agent discovered by FUJIFILM Toyama 
Chemical Co., Ltd. It is a broad -spectrum antiviral that includes activity against all RNA virus 
families tested, including rabies, Ebola, Lassa , and coronaviruses. It has been in clinical trials for 
influenza, Severe Fever with Thrombocytopenia virus, Ebola, and has been used under compassionate release for Ebola, rabies, Lassa fever, norovirus and COVID -19. As of the date of 
this protocol, three  Chinese studies exploring its use against COVID -19 have been posted to the 
Chinese Clinical Trial Registry website ( http://www.chictr.org.cn/showprojen.aspx?proj=49042 
http://www.chictr.org.cn/showprojen.aspx?proj=49015 http://www.chictr.org.cn/showprojen.aspx?proj=49013).  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 15 of 43  Results from one study have been reported as demonstrating that viral PCR titers fall faster in 
patients treated with favipiravir plus interferon as compared with patients treated with interferon plus lopinavir/ritonavir. 
Host cellular enzymes convert favipiravir to T -705 ribosyl  triphosphate (T -705RTP), which 
selectively inhibits viral RNA polymerase. Based on its potent and selective inhibitory activities 
against a broad spectrum of influenza A, B, and C viruses, including strains poorly susceptible to amantadine hydrochloride o r oseltamivir phosphate, favipiravir has been approved in Japan for 
the treatment of uncomplicated influenza, when currently available anti -influenza medications 
are not sufficient.  
Favipiravir has been tested against the novel corona virus COVID -19, which  causes disease 
ranging from mild, cold -like symptoms to acute respiratory failure and death. Epidemiol ogic 
studies are underway to determine whether individuals can be asymptomatic and transmit disease.  T here is currently no available treatment for COVID -19. 
2.2 Preclinical and In Vitro Experiences  
Preclinical and animal studies indicate that favipiravir is effective against RNA viruses causing a variety of disorders. 
Preclinical and animal studies show no direct suppression of white blood cell types or 
immun osuppression by favipiravir. This contrasts with strong immunosuppressive effects of 
ribavirin and other antiviral agents. 
Genotoxicity studies indicate that favipiravir does not pose a clinical genotoxic risk, however, 
based on the results of embryo- fetal toxicity studies, favipiravir is not recommended for use in 
pregnant females, those who may become pregnant, or those who are nursing. A human testicular toxicity study was run to determine if there are effects on human spermatogenesis. No abnormality in testicular function tests was observed; however, this study was performed at 
doses less than those to be used in this study. Due to the effect on embryo -fetal development 
seen in animals, and the presence of favipiravir in semen for several days after the end of therapy, the recommendation is for male and female contraception for seven days following the end of treatment, in the dose regimen for influenza. Details of the reproductive toxicity studies may be found in the Investigator’s Brochure. 
Favipiravir is both metabolized by, and inhibits, aldehyde oxidase (AO). A potential interaction 
exists between favipiravir and drugs oxidatively metabolized by the AO pathway, where blood 
concentration of these drugs or favipiravir may be increased. Similarly, a pote ntial interaction 
exists between favipiravir and drugs inhibiting AO activity, where blood concentration of favipiravir may be increased. Similarly, a potential interaction exists between favipiravir and drugs inhibiting AO activity, where blood concentration of favipiravir may be increased. Favipiravir should not be used with pyrazinamide. 
2.3 Clinical Experience 
Overall, more than  40 clinical studies with favipiravir have been conducted globally, mainly in 
the US and Japan . Recently, China has begun studying favipiravir in patients with severe 
influenza as well as COVID -19. More than  3100 study subjects have received at least one dose 
of favipiravir  manufactured by Toyama Chemical . Favipiravir has been well tolerated in studi es 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 16 of 43  in adults and elderly subjects  with uncomplicated influenza . A consistent safety profile 
composed of relatively low frequencies of mild to moderate adverse events (AEs) clustering 
around the system organ classes of gastrointestinal disorders, investigations, and infections and infestations has been characterized. Mild to moderate transient, asymptomatic elevations in serum uric acid and mild to moderate diarrhea are the two most common AEs known to occur 
with favipiravir.  In double blind studies, the adverse event profile of favipiravir and placebo 
were similar with the exception of elevations of uric acid. Details can  be found in the 
Investigator’s B rochure.  
Favipiravir has been used in an open label study in patients with Ebola, (2400 mg twice eight hours apart, followed by 1200 mg 8 hours later and then 1200 mg BID for the following 9 -13 
days) . Although conclusions about efficacy cannot be reached because of the lack of a 
concurrent control group, favipiravir at this regimen appeared to be well tolerate d. A study in 
Japan in patients with Severe Fever with Thrombocytopenia administered 1800 mg BID Day 1 followed by 800 mg BID for the next 13 days. It has also been used under compassionate use in 
patients with rabies  or other unusual RNA virus illnesses. 
2.4 In Vitro Therapeutic Levels  
Recent in vitro experiments indicate that therapeutic levels for SARS -CoV- 2 should be 
achievable, as illustrated in the following table : 
Virus  USAMRIID  Literature  
 IC50 (µg/ml)  
SARS -CoV -2  9.71 (EC 50) 
Influenza   < 42 
SFTS   < 43 
Lassa (Josiah)  10 4.644 
Marburg  9.9  
MERS -CoV  35.2  
Ebola  66 475 and 10.56 
1. Wang, et al, Cell Research  2020 p1 -3 
2. Sleeman, et al , Antimicrob Agents Chemo  2010 54 p2517 
3. Baba, et al, Antivir Chem Chemother 2017 25 p83 
4. Oestereich, et al, J Infect Dis  2016 213  p934 
5. Smithers, et al, Antivir Res  2014 104  p153 
6. Oestereich, et al, Antivir Res  2014 105  p17 
2.5 Phase 1 Study Steady State Exposure  
In a Phase 1 study in Japan, steady state exposures above the influenza target were achieved, which should cover the necessary exposure for SARS -CoV-2. 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 17 of 43   
Similar to the PK profile above, the studies in the global influenza program using 5 -days of 
treatment, demonstrated a similar PK profile, albeit with lower exposures.  Below is the graph 
from US316, one of the US pivota l trials, a five -day study of 1800 mg BID Day 1 followed by 
800 mg BID Days 5. As can be seen, the mean daily trough levels were above the target level of 
20 ug/ml. 
Below is the same graph for US317, the second pivotal trial in the program. 

FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 18 of 43   
2.6 Rationale for 14-day Dosing Regimen 
A Chinese study  reported that patients in the control group (Ketruda plus aerosolized interferon) 
shed virus for a mean of 11 days, and the mean time to clearance in the group on favipiravir plus 
interferon was four days. Therefore, a mean time treatment duration of 14 days was chosen, in 
case interferon plus favipiravir was more effective than favipiravir alone, given the safety data supporting treatment of 10 days and beyond. 
• (https://www.sciencedirect.com/science/article/pii/S2095809920300631
) 
2.7 Rationale for the C urrent S tudy  
There is a global pandemic caused by the SARS -CoV- 2 virus, which threatens the lives of many 
and the economic stability of the  world . Therapeutic approaches are badly needed, and an orally 
available, well tolerated small molecule agent could play a critical part in preventing and 
ameliorating COVID -19. 
Evidence from non- clinical (cell culture) experiments and recently reported clinical experience 
in China, indicates that favipiravir may have clinical benefit in patients infected with SARS -
CoV- 2. Favipiravir has been shown to be active against all families of RNA viruses in which it 
has been tested. Clear antiviral activity (faster  cessation of viral shedding) has been demonstrated 
in the influenza studies.  Patients with influenza have recovered more quickly than placebo controls. 
People who have been hospitalized to treat acute respiratory symptoms in the US have no proven 
option other than supportive care, which includes mechanical ventilation, oxygen therapy and 
treatment of co -infections and organ failure if needed. The safety profile of favipiravir is well -
established. It is generally safe and well -tolerated with the exception of transient elevations of 

FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 19 of 43  uric acid that resolve with cessation of dosing. Thus, the risk to benefit assessment of treatment 
with favipiravir in the face of COVID-19 is clearly in favor of potential study subjects. 
This study will assess the time course o f cessation of viral shedding, and gather clinical benefit 
information, in patients with COVID -19 treated with favipiravir as compared to control. Data 
from this trial is expected to support a larger study which will demonstrate clinical benefit and 
serve as a pivotal trial for approval. The information gathered from this study will also help 
define the safety profile in this setting and enable expansion into other patient populations such as those who have been exposed but who are not yet ill. This could have a significant impact on public health. 
3 DESIGN 
This is an open label, randomized, controlled, multicenter Phase 2 study of favipiravir in hospitalized subjects with COVID -19. Subjects will be randomized within their study site and 
stratified by the severity of their disease to receive either favipiravir + standard of care (SOC) or 
SOC alone (See Section 9.5 for details) . 
SOC will be site -specifi c and based on what each site is currently using for COVID-19 patients. 
The dose regimen will be 1800 mg favipiravir BID plus SOC or SOC alone on Day 1 followed by 1000 mg BID favipiravir (800 mg BID for subjects with Child-Pugh A liver impairment) plus 
SOC or SOC for the next 13 days. 
The study will have 14 days of treatment and 46 days of follow -up. 
4 OBJECTIVES 
4.1 Primary Objective  
• To determine the effect of favipiravir + SOC v. SOC on viral clearance  
4.2 Secondary Objectives   
1. To determine the clinical benefit of administering favipiravir plus SOC compared to SOC 
alone [assessed using a study -specified 6 -point ordinal scale adapted from the WHO Master 
Protocol (V2.0 24FEB20) COVID -19 7- point ordinal scale]  in adult patients hospitalized 
with COVID -19. 
2. To determine if the treatment effect on the 6 -point ordinal scale, on Day 15, is reasonably 
likely to reflect clinical benefit, such that it can be used as the primary clinical outcome endpoint in a similar study that is double -blinded, by assessment of the relationship of the 
scale to changes in clinical and symptom outcomes, including time to clinical recovery, 
occurrence of fever, cough, dyspnea, reduction in oxygen requirements, and other measures. 
3. To explore the clinical effect of favipiravir + SOC v. SOC as measured by the NEWS 2 
system.  
4. To determine the safety of favipiravir plus SOC compared to SOC alone, in this population. 
5. To explore the PK of this dose regimen of favipiravir in this patient population. 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 20 of 43  5 SUBJECT POPULATION  
5.1 Inclusion Criteria  
All criteria must be  confirmed  as “YES”: 
1. Adults (18 to 80 years old): 
a. within 72 hours of their hospitalization  for infection with SARS-CoV-2, AND,  
b. within 72 hours of the latest PCR positive result and within 7 days of the 1st PCR positive 
result for SARS -CoV-2. (The latest PCR could be the only PCR result .), AND, 
c. within 10 days of onset of any COVID-19 symptoms. 
2. Subject or their legal representative understands the requirements of the study and provides 
written informed consent prior to undergoing any treatment- related procedures.  
3. If male, subject must:  
a. Be sterile (e.g., have had a vasectomy at least 6 months prior to Day 1 dosing), OR, 
b. Agree not to donate sperm during the study and for seven days following the last  dose of 
study medication, AND, 
c. Agree to strictly adhere to the following contraceptive measures during the study and for  
seven days following the last dose of study medication: 
i. Abstain from sexual intercourse. 
ii. Use a condom during sexual intercourse with a female of c hild-bearing  potential. In 
addition, the female partner must use another form of  contraception (e.g. intrauterine 
device [IUD], diaphragm with spermicide, oral  contraceptives, injectable 
progesterone, or subdermal implants).  
4. If female, subject must:  
a. Be un able to bear children (have not had a period for ≥ 12 consecutive months, have  had 
her uterus or ovaries removed, or have had a tubal ligation), OR, 
b. Must ensure that their male partner is incapable of fathering a child (e.g., has had a vasectomy at least  6 months prior to study entry), OR,  
c. If she is of childbearing potential will strictly adhere to the following contraceptive  
measures during the study and for seven days following the last dose of study medication: 
i. Abstain from sexual intercourse, OR, 
ii. Must ensure that her male partner agrees to use a condom during sexual intercours e 
and agree to use an approved method of contraception (e.g., IUD, diaphragm with  
spermicide, oral contraceptives, injectable progesterone, or subdermal implants).   
d. Agrees to stop breast -feeding prior to first dose of study drug and through seven days 
after completing therapy.  
e. Has a negative pregnancy test at screening.  
f. Has not had unprotected sexual intercourse within the past month. 
5.2 Exclusion Criteria  
All criteria must be confirme d as “NO”: 
1. Subject has a concomitant bacterial respiratory infection unless cleared by the Sponsor . 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 21 of 43  NOTE:  Subjects on empirical antibiotic treatment for possible 
but unproven bacterial pneumonia, but who are positive for 
SARS -CoV-2, are allowed in the stud y. 
2. Subject has a history of abnormalities of uric acid metabolism unless cleared by the Sponsor. 
3. Subject has a history of hypersensitivity to an anti -viral nucleoside -analog drug targeting a 
viral RNA polymerase 
4. Subject is using adrenocorticosteroids (except topical or inhaled preparations  or oral 
preparations equivalent to or less than 10 mg of oral prednisone) or immunosuppressive  or 
immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, 
interleukin antagonists or interleukin receptor blockers ). 
NOTE: Treatment of study participants following 
institutional COVID -19 treatment policies or guidelines, 
including the use of immunomodulatory medications, is permitted . Per the conclusions of The Randomised Evaluation 
of COVID -19 therapy (RECOVERY) trial 
(https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1; accessed 13Jul2020), dexamethasone 6 mg daily (PO or IV) for 10 days is permitted. This excludes treatment with 
agents that have the potential for direct antiviral activity, including convalescent plasma and NO, and co- enrolment into 
other clinical studies that evaluate investigational agents for COVID -19. 
5. Subject has a serious chronic disease (e.g., human immunodeficiency virus [HIV], cancer requiring chemotherapy within the preceding 6 months, moderate or severe hepatic 
insufficiency and/or unstable renal, cardiac, pulmonary, neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days). 
6. Has previously received favipiravir within the past 30 days. 
7. Has renal insufficiency requiring hemodialysis or continuous ambulatory peritoneal dialysis (CAPD).  
8. Has liver impairment greater than Child -Pugh A .  (NOTE: Child -Pugh A subjects will have 
the maintenance dose decreased to 800 mg BID). 
9. Has a history of alcohol or drug abuse in the previous 6 months. 
10. Has a psychiatric disease that is not well controlled where controlled is defined as: stable on a regimen for more than one year.  
11. Has taken another investigational drug within the past 30 days. 
12. Is on another antiviral or is participating in a clinical trial for the treatment of COVID -19. 
13. Is on a ventilator at the time of study entry.  
14. Is deemed by the Investigator to be ineligib le for any reason.  
5.3 Removal of Subjects from Treatment  
The participation of a subject in the study or the administration of treatment may be terminated at any time for one of the following reasons: 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 22 of 43  • The subject desires to discontinue study treatment. 
• The subject withdraws consent to participate in the study.  
• The subject is unwilling or unable to comply with the safety procedures. 
• The subject is discovered to be pregnant.  
• The subject experiences a medical emergency that necessitates withdrawal.  
• The subject is  withdrawn at the discretion of the Investigator for medical reasons or non - 
compliance.  
5.4 Individual Stopping Rule  
In addition to the above, a. subject should be removed from favipiravir treatment if one of the 
following criteria is met: 
• AST or ALT > 8 × ULN  
• ALT or AST > 3 × ULN AND total bilirubin > 2  × ULN  
• AST or ALT > 3 × ULN AND patient has right upper quadrant pain or eosinophilia 
• Uric acid > 20mg/dL  
A subject whose treatment is terminated should remain in the study for appropriate follow up assessme nts. 
6 STUDY TREATMENT  - FAVIPIRAVIR 
6.1 Study Drug  
Favipiravir will be provided in 200 mg tablet form to be stored at controlled room temperature 
(15°C to 30°C [59°F to 86°F]) and shielded from light. 
6.2 Standard Dose  
Subjects randomized to the favipiravir + SOC a rm will be administered loading doses of 1800 
mg  BID (Ideally 12 hours apart but 10–16 hours  is allowed) on Day 1 , and then maintenance 
dosing of 1000 mg twice daily  BID (Ideally 12 hours apart but 10–16 hours is allowed) on Days 
2–14 beginning 24 hours after the first dose . Day 1 is deemed to be the first 24 hours after 
enrollment into the study, with time 0 (time of first dose) occurring as soon as possible after the 
subject’s eligibility has been confirmed.   
An exception to the above maintenance dose will be made for those subjects entering the study with a Child -Pugh liver impairment of grade A who will receive favipiravir 800 mg BID on 
Days  2 through 14.  
6.3 Administration of Favipiravir  
Favipiravir is  provided as 200 mg tablets and dosed orally . Favipiravir is rapidly and completely 
absorbed after oral administration of the 200 mg immediate release tablets.  
If a subject cannot swallow the tablets, a slurry may be administered by nasogastric (NG) or 
orogastric (OG) tube. (Instruction s for preparing the slurry are provided in the pharmacy 
instructions.). If an NG or OG tube cannot be placed, the favipiravir tablets can be crushed and 
administered in a “masking” substance such as apple sauce or cranberry juice.  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 23 of 43  Subjects  who vomit during or immediately after dosing, should not be re-dosed. 
The Investigator must consult with the Sponsor Medical Monitor prior to adjusting the dose 
level, regimen, or route of dosing. 
6.3.1 Outpatient Favipiravir Dosing 
It is possible that some subjects may improve sufficiently to be discharged from the hospital 
prior to Day 14. If this happens, subjects in the favipiravir + SOC arm, will be dispensed 
sufficient favipiravir to ensure continued dosing until their next stud y visit. Subjects will also be 
given a Diary Card to record the date and time they take their dose. 
Subjects will also be instructed that if they miss a dose, they should follow the guidelines: 
1) If more than 1/2 the time until their next dose has elapsed, they SHOULD NOT take the 
dose. They should just take the next dose at the normal scheduled time. 
2) If less than 1/2 the time until their next dose has elapsed, they should take the missed dose 
immediately.  
3) In both cases, they should then return to their regular dosing schedule. 
6.4 Drug Accountability  
The Investigator must maintain adequate records showing the receipt, dispensation, or other 
disposition of favipiravir including the date, quantity , and identification of subjects ( study ID ) 
who received fav ipiravir. Drug supplies will be inventoried and accounted. U nused supplies of 
all favipiravir will be returned to the Sponsor or destroyed on site in accordance with local 
procedures upon approval of the Sponsor. 
6.5 Treatment Compliance  
All doses of study drug will be administered by site staff  while in the hospital. If the patient is 
discharged while still on drug, the pharmacy will provide bottles of favipiravir for outpatient use (Exact dispensing instructions for outpatients will be described in the pha rmacy instructions) . 
Assessment for compliance with each dose will be monitored and recorded in accordance with site standard operating procedures. 
6.6 Treatment Precautions  
An overdose is defined as any dose of study drug given to a subject or taken by a subj ect that 
exceeds the dose described in this document. In the event of an overdose, the subject should be treated symptomatically,  and the Sponsor informed. 
6.7 Prohibited Concomitant Therapy  
The following may interact with favipiravir and risks and benefits should be carefully  considered 
prior to treatment with the following:  
• Any other anti- viral medication  whether investigational or approved. 
• Any drugs known to significantly inhibit AO activity ( e.g., pyrazinamide, amitriptyline, 
chlorpromazine, clomipramine, clozapine, erythromycin, ketoconazole, nortriptyline, 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 24 of 43  quetiapine, raloxifene, perphenazine, promethazine, propafenone, tamoxifen, 
thioridazine). 
• Any drugs metabolized by the AO pathway (e .g., famciclovir, hydralazine, lamivudine, 
sulindac, zaleplon, ziprasidone). 
• Drugs with possible drug- drug interactions (concomitant medications requiring particular 
attention  – see the Investigator Brochure).  
For hospitalized subjects on the favipiravir + SOC arm, site staff will be reminded to consider the above prior to prescribing concomitant medications. The following message appears on the Diary Card given to subjects that are discharged with favipiravir to take at home (see Section 6.3.1): 
Favipiravir can slightly increase the concentration of acetaminophen (Tylenol) in the blood.  Do not take more than 3000 mg (do not forget to include any acetaminophen that 
could be in over -the- counter preparations) in a 24- hour period as long as you are taking 
favipiravir.  
There are possible interactions of favipiravir with other drugs . During the time that you 
remain on favipiravir, do not take any medications or supplements that you were not taking while you were in the hospital, without getting approval first from the study doctor. 
Favipiravir can cause you to be mildly sens itive to sunlight.  Please avoid excessive exposure to 
sunlight or artificial ultraviolet light (tanning machines) while you are on favipiravir.  
7 STUDY P ROCEDURES  
Refer also to Section 13: Schedule of A ssessments  
7.1 Day 1 (P RE-DOSE )  
• Obtain informed consent. 
• Verify eligibility per  the inclusion and exclusion criteria. (See Section s 5.1 and 5.2) 
o Review and record medical history , including tobacco use, to ensure there are no 
exclusionary illnesses.  
o Review and record concomitant medications for possible prohibited medications.  (See Section 6.7) 
• If subject is female of  child -bearing potential and meets inclusion criteria 4.c, obtain urine  or 
blood pregnancy test and proceed it result is negative. 
• Measure and record vital signs  (BP, HR, Temp, Resp). 
NOTE:  vital signs to be recorded and entered in the EDC every day while subject is in the 
hospital and on return study visits after discharge. 
• Perform Physical exam (may be done by the Principal Investigator or their designee)  
• Assess and r ecord baseline clinical status according to the following study- specific 6-point 
scale:  
1. Not hospitalized  
2. Hospitalized, not requiring supplemental oxygen 
3. Hospitalized, requiring supplemental oxygen 
4. Hospitalized, on non-invasive ventilation or high flow oxygen devices  
5. Hospitalized, on invasive mechanical ventilation or ECMO  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 25 of 43  6. Death  
NOTE:  Clinical Status to be recorded and entered in the EDC every day while subject is in 
the hospital and on return study visits after discharge. 
• Assess and record NEWS 2 (See charts by clicking this link: 
https://www.rcplondon.ac.uk/projects/outputs/national- early -warning- score -news -2 
NOTE:  NEWS2 assessment to be recorded and entered in the EDC every day while subject 
is in the hospital and on return study visits af ter discharge.  
• Assess and record ECOG Performance Status and Study -specific Symptom Status (see 
Appendix A). 
NOTE:  ECOG Performance Status and Study -specific Symptom Status to be collected and 
recorded every day w hile the subject is in the hospital and on return study visits after 
discharge.  
• Collect nasopharyngeal and oropharyngeal swabs  for virologic testing.  (See Virology 
Laboratory Manual. ) 
• Collect blood samples for: 
o Antibodies to SARS- CoV -2. 
o Hematology  and clinical  chemistry  laboratory analyses  
• Collect and record S pO2 by Finger Sensor 
NOTE:  SpO2 to be recorded and entered in the EDC every day while subject is in the 
hospital and on return study visits after discharge. 
• Perform subject randomization (via EDC) to establish treatment arm (favipiravir + SOC or SOC alone).  
• For subjects randomized to favipiravir: Collect blood sample for PK prior to first dose (refer to PK laboratory manual for handling and shipping instructions). 
7.2 Day 1 ( FIRST DOSE AND POST -DOSE)  
NOTE:  Day 1 is deemed to be the first 24 hours after enrollment into the study, with time 0 (time 
of first dose) occurring as quickly as possible after the subject’s eligibility has been confirmed.  
• Administer first dose (1800 mg) at time 0 . 
Following First Dos e: 
• For subjects randomized to favipiravir, collect blood sample for  PK within 45 to 75 minutes 
post-dose 
• Measure and record vital signs (BP, HR, Temp, Resp). 
• Collect  and record S pO2 by Finger Sensor 
• Administer second dose (1800 mg) at time 0 + 12 hours. 
• Perform limited PE to focus on heart and lungs (may be done by the Principal Investigator or 
their designee) . 
NOTE:  to be done every day while the subject is in the hospital and on return study visits 
after discharge  
• Collect and record adverse events (see Section 8.4 for detailed instructions)  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 26 of 43  7.3 Days 2 and 14 
• Measure and record vital signs  (BP, HR, Temp, Resp). 
• Perform a limited PE to focus on heart and lungs. 
• Review and record concomitant medications (Note:  if there have been changes in 
concomitant medications during the study, determine whether the change is due to an AE). 
• For subjects randomized to favipiravir collect blood sample for PK  analysis at 30 minutes 
prior to any dose 
• Collect and record adverse events (see Section 8.4 for detailed instructions)  
• Collect and record S pO2 by Finger Sensor 
• Assess and record clinical status according to the following study- specific 6-point scale: 
1. Not hospitalized  
2. Hospitalized, not requiring supplemental oxygen 
3. Hospitalized, requiring supplemental oxygen 
4. Hospitalized, on non-invasive ventilation or high flow oxygen devices  
5. Hospitalized, on invasive mechanical ventilation or ECMO  
6. Death  
• Assess and record NEWS2  
• Assess and record ECOG Performance Status and Study -specific Symptom Status (see 
Appendix A). 
• Collect and record adverse events (see Section 8.4 for detailed instructions).  
7.4 Days 3, 8 and 11 
• Collect blood samples for hematology and clinical chemistry laboratory analyses  
• On Day 8 ± 1 day only: For subjects randomized to receive favipiravir, collect blood 
samples for PK trough analysis at 30 minutes prior to any dose 
• On Days 3 and 11 ± 1 day : For subjects randomized to receive favipiravir, collect blood 
samples for PK peak analysis at 45 -75 minutes after any dose. 
• Measure and record vital signs (BP, HR, Temp, Resp). 
• Perform a limited PE to focus on heart and lungs. 
• Review and record concomitant medications (Note: if there have been changes in 
concomitant medications during the study, determine whether the change is due to an AE). 
• Collect and record S pO2 by Finger Sensor 
• Assess and record clinical status according to the study- specific  6-point scale: 
1. Not hospitalized  
2. Hospitalized, not requiring supplemental oxygen 
3. Hospitalized, requiring supplemental oxygen 
4. Hospitalized, on non-invasive ventilation or high flow oxygen devices  
5. Hospitalized, on invasive mechanical ventilation or ECMO  
6. Death  
• Assess and record NEWS2  
• Collect nasopharyngeal and oropharyngeal swabs for virologic testing.  
• Collect and record adverse events (see Section 8.4 for detailed instructions ). 
• Assess and record ECOG Performance Status and Study -specific Symptom Status (see 
Appendix A). 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 27 of 43  7.5 Days 15 and 29 (Follow-up) or Early Termination 
• Perform a limited PE to focus on heart and lungs. 
• Review and record concomitant medications (Note: if there have been changes in 
concomitant medications during the study, determine whether the change is due to an AE). 
• Measure and record vital signs (BP, HR, Temp, Resp). 
• Collect and record S pO2 by Finger Sensor 
• Collect blood samples for:  
o Antibodies to SARS- CoV -2. 
o Hematology and clinical chemistry laboratory analyses  
• Assess and record clinical status according to the following study- specific 6 -point scale: 
1. Not hospitalized  
2. Hospitalized, not requiring supplemental oxygen 
3. Hospitalized, requiring supplemental oxygen 
4. Hospitalized, on non-invasive ventilation or high flow oxygen devices  
5. Hospitalized, on invasive mechanical ventilation or ECMO  
6. Death  
• Assess and record NEWS2  
• Collect nasopharyngeal and oropharyngeal swabs for virologic testing.  
• Collect and record adverse events (see Section 8.4 for detailed instructions).  
• Assess and record ECOG Performance Status and Study -specific Symptom Status (see 
Appendix A).  
Note:  Day 15 visit procedures may be conducted on Day 14 if patient is discharged before 
Day 15. 
7.6 Days 45 and 60 (Additional Safety Follow- up) 
Follow up assessment of general health and well -being may be done while the subject remains 
hospitalized or  by phone if  the subject has been released from the hospital  and is unable to return 
for the study visit.  
• Measure and record vital signs (BP, HR, Temp, Resp). 
• Perform a limited PE to focus on heart and lungs. 
• Review and record concomitant medications (Note: if there have been changes in 
concomitant medications during the study, determine whether the change is due to an AE). 
• Collect and record S pO2 by Finger Sensor 
• Assess and record clinical status according to the following study- specific 6 -point scale: 
1. Not hospitalized  
2. Hospitalized, not requiring supplemental oxygen 
3. Hospitalized, requiring supplemental oxygen 
4. Hospitalized, on non-invasive ventilation or high flow oxygen devices  
5. Hospitalized, on invasive mechanical ventilation or ECMO  
6. Death  
• Assess and record NEWS2  
• Administer the ECOG Performance Status questionnaire. (See Appendix A) 
• Administer the  Study- specific Symptom Status questionnaire. (See Appendix A)  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 28 of 43  • Collect and record adverse events (see Section 8.4 for detailed instructions).  
NOTE:  if the visit is conduc ted by phone, vital signs, limited PE, SpO2, and NEWS2 will not be 
evaluated.  
7.7 Day of Discharge from Hospital 
• Some subjects may be well enough for discharge from the hospital prior to completing the 
full 14 days of treatment. In these cases, the following procedure should be followed 
• FOR ALL SUBJECTS (regardless of treatment assignment)  
o The study staff will collect nasopharyngeal and oropharyngeal swabs, regardless of which 
study day the subject is discharged  (e.g., samples should be collected on subjects 
discharged from the hospital on Study Day 4 even though they will have had this procedure on Study Day 3, per protocol.) 
• FOR SUBJECTS TAKING FAVIPIRAVIR  
o The study staff will request the pharmacy to dispense the appropriate number of tablets for the subject to take between the time of discharge and the next scheduled study visit  
plus one extra day in case the visit must be changed.  Prior  to each study visit, the study 
staff will request a “refill” of  favipiravir tablets to be taken by the subject between the 
time of the current visit and the subsequent visit. (See Pharmacy Instructions for details 
of dispensing.) 
o To assist the subject with compliance, dosing instructions will be provided along with the favipiravir.  
o Subjects will be reminded that the Rx bottle MAY NOT BE RETURNED  TO (LEFT 
AT) THE SITE. To avoid contamination, each subject will bring the bottle and unused 
drug to their visit and show the contents of the bottle to the study staff conducting the 
visit. Once the drug has been counted, the subject will be instructed to dispose of the pills by placing them in a separate bag and putting the bag in the on- site trash.  
o NOTE: the site may make modifications to this procedure if needed to comply with local rules for non- contamination of the site.  
o When a subject completes dosing (either by completing all 14 days of dosing or by leaving the study) the pharmacy will send the Subject IP accountability log to the Sponsor for verification with the EDC and compliance with the protocol. 
8 EFFICACY, PHARMACOKINETICS AND SAFETY A SSESSMENTS  
8.1 Efficacy Assessments  
Efficacy will be assessed by the following measurements:  
• Presence of virus in the naso pharyngeal and oropharyngeal samples taken on Days 1, 3, 8, 
11, 15 and 29 (if hospitalized and when able to return to clinic after discharge). Swabs will 
also be obtained on day of discharge from hospital if discharge occurs before Day 15. 
• Clinical improve ment of hospitalized subjects with COVID- 19 receiving either favipiravir + 
SOC or SOC alone as defined by the following study- specific 6-point ordinal scale at Day 15 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 29 of 43  1. Not hospitalized  
2. Hospitalized, not requiring supplemental oxygen 
3. Hospitalized, requiring supplemental oxygen 
4. Hospitalized, on non-invasive ventilation or high flow oxygen devices  
5. Hospitalized, on invasive mechanical ventilation or ECMO  
6. Death  
• Status on the study specific 6-point ordinal scale assessed daily while hospitalized 
and at each outpatient visit until Day 60 . 
• NEWS 2 assessed daily while hospitalized and at each outpatient visit until Day 60 . 
• Patient status assessed daily while hospitalized and at each outpatient visit until Day  60 via 
Study- specific Symptom Status and the ECOG Performance Status questionnaires (see 
Appendix A). 
• Duration of supplemental oxygen (if applicable).  
• Duration of mechanical ventilation (if  applicable).  
• Duration of hospitalization.  
• Date and cause of death (if  applicable).  
• PCR and TCID50 in nasopharyngeal and oropharyngeal swabs on D ays 1 , 3, 8, 
11, 15 and 29 (if hospitalized and when able to return to clinic after discharge), 
and on day of discharge if hospital discharge occurs before Day 15. 
• Blood for determination of antibodies to SARS- CoV -2 obtained on Days 1, 15 and 29 (if 
hospitalized and when able to return to clinic after discharge). 
8.2 Required Resistance Testing  
Resistance testing , as required in clinical trials of anti- viral drugs will be performed using one of 
the swabs, at each time point that nasopharyngeal and oropharyngeal swabs are taken.  
8.3 Pharmacokinetics/Pha rmacodynamics Assessments  
• 6.0 mL of blood will be collected for PK sampling on: 
o Day 1 pre- and post-dosing (1st dose) 
o Days 2, 8 and 14 pre-dosing (any dose)  
o Days 3 and 11 post-dosing (any dose)  
• Kits for each PK draw  and instructions for handling and shipping are provided by the PK 
analysis laboratory . 
8.4 Safety Assessment s 
Abnormal clinical laboratory values that are clinically significant and all reported advers e events 
will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0. 
Safety will be assessed by the collection of observed and reported adverse events, physical 
exams , vital signs , and the following clinical laborato ry tests:  
• Hematology 
Hemoglobin (Hgb)  Hematocrit (Hct)  
Platelet count  Red blood cell count  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 30 of 43  White blood cell count with differential  
• Chemistry  
Blood Urea Nitrogen (BUN)  Creatinine  
Total bilirubin  Alkaline Phosphatase  
Aspartate transaminase (AST)  Alanine transaminase (ALT)  
Gamma -glutamyl transferase (GGT)  Lactic dehydrogenase (LDH)  
Glucose  Albumin  
Total protein  Bicarbonate  
Phosphate  Sodium  
Potassium  Chloride  
Calcium  Total cholesterol  
Urate  C-reactive protein  
D-dimer  
 
NOTE S: 
• All clinical laboratory assessments listed above (hematology and chemistry) will be 
conducted at each site’s local clinical laboratory.  
• If coagulation assays are ordered as part of the SOC, the results should be added to the EDC.  
Including PK and Clinical Laboratory Testing, subjects will undergo 9 planned venipunctures 
during this study. 
8.4.1 Adverse Events  
Treatment -emergent AEs will be defined as those occurring coincident with start of treatment 
through 46 days post- treatment  (Day 60). 
In the favipiravir + SOC arm:  Adverse event solicitation and recording will begin immediately 
following the first dos e of favipiravir  and will include only on- treatment  (treatment emergent ) 
events. Any changes to a subject’s health that occur between the signing of the informed consent  
and dosing will be recorded as updates to the subject’s medical history. 
In the SOC alone arm:  Adverse event solicitation and recording will begin following the 
completion of all baseline assessments.  
Subjects will be instructed to report AEs during the study and staff will query subjects regarding 
AEs throughout the study. The Investigator (and/or designee) must document all AEs reported through completion of the Day 60 visit. Any subject who is withdrawn from the study due to an 
AE shall be followed until the event has resolved or stabilized or , if in the favipiravir arm,  14 
days after last dose . The Investigator will document available follow -up information on the 
subject’s source documentation and CRF. 
8.4.2 Definition of an Adverse Event  
The FDA Safety Guidance, referencing 21CFR312.32(a), defines an Adverse Event as follows: 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 31 of 43  Adverse event means any untoward medical occurrence associated with the use of a drug 
in humans, whether or not considered drug related. 
An adverse event (also referred to as an adverse experience) can be any unfavorable  and 
unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a drug and does not imply any judgment about causality. An adverse event can arise with any use of the drug (e.g., off -label use, use in combination 
with another drug) and with any route of administration, formulation, or dose, including an overdose.  
Adverse Events are NOT : 
• Clinical events related to the progression of COVID -19. 
• Medical or surgical procedures ( e.g., surgery, endoscopy, tooth extraction, transfusion).  
The condition that leads to the procedure is the AE. 
• Situations where an untoward medical occurrence has not occurred ( e.g., hospitalization 
for elective surgery, social and/or convenience admissions) . 
8.4.3 Evaluating and Reporting of Adverse Events 
All AEs (i.e.  a new event or an exacerbation of a pre- existing condition) that occur after dosing 
with favipiravir and after completion of baseline assessments in the SOC alone arm, must b e 
recorded as an AE or SAE  (if applicable),  on the Adverse Event e CRF and SAE form, as 
applicable. The Investigator must follow a ll AEs until the AE resolves, or until the Investigator 
and/or the Medical Monitor  determine the event is chronic or clinically  stable. If an AE remains 
unresolved at the conclusion of the study, the Investigator and Medical Monitor will make a  
clinical assessment to determine whether continued follow -up of the AE is warranted. All 
subject s who have received at least one exposure to study therapy will be evaluated for safety of 
study treatment.  
The Investigator should attempt to establish a diagnosis of the event based on signs, symptoms and/or other clinical information. In such cases, the diagnosis should be documented as the AE 
and not the individual signs/symptoms. 
All AEs must be promptly documented on the Adverse Event eCRF  and assessed by the 
Investigator. Details of the event must include the dates of onset and resolution, severity, 
relationship to study drug, seriousness, a nd whether the event caused the subject  to withdraw 
from the study, outcome and timing with regard to administration of the study drug. 
Severity:  Severity should be graded and recorded as follows: 
• Mild: Awareness of event but easily tolerated  
• Moderate: Dis comfort enough to cause interference with usual activity 
• Severe: Inability to carry out usual activity, incapacitating, requires medical intervention  
Relationship:  The relationship of the Adverse Event to the study drug will be determined by the 
Principal Investigator, and assessed using the following definitions: 
• Related : There is a distinct temporal relationship between the event onset and 
administration of the study drug. There is a known reaction to agent or chemical group or 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 32 of 43  predicted by known pharmacology. The event cannot be explained by subject ’s clinical 
state or other factors.  
• Unrelated:  Evidence exists that the AE has an etiology other than the study drug (e.g., 
pre-existing condition, underlying disease, intercurrent illness, or concomitant 
medication).  
These criteria, in addition to good clinical judgment, should be used as a guide for determining 
the causal assessment. If it is felt that the event is not  related to study drug therapy, then an 
alternative explanation should be provided. 
8.4.4 Serious Adverse Events (SAEs)  
All SAEs as defined below and that occur after the first dose of favipiravir and up to Day 60 
(which is 46 days after the last planned study drug administration)  must be reported to the 
Sponsor as soon as the site becomes aware of them. Any SAEs occurring after Day 60 (more 
than 46 days after last planned study drug administration) and considered at least possibly drug-
related must also be reported.  
 
8.4.5 Definition of Serious Adverse Events   
An SAE is an AE from this study that results in any of the following outcomes:  
• Death ( even if caused by  COVID-19 all deaths are recorded as SAEs ) 
• Life-threatening situation ( subject  is at immediate risk of death ) 
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant disability/incapacity  
• Congenital anomaly/birth defect in the offspring of a subject  who received study drug 
NOTE: Important medical events that may not r esult in death, be immediately life -threatening, or 
require hospitalization, may be considered an SAE when, based upon appropriate medical 
judgment, they may jeopardize the subject  and may require medical or surgical intervention to 
prevent one of the outc omes listed in this definition.  
A life -threatening AE is defined as any adverse experience that places the subject  in the view of 
the Investigator, at immediate risk of death from the event as it occurred. This does not include an event that might have led  to death, if it had occurred with greater severity. 
“Inpatient hospitalization” means the subject  has been formally admitted to a hospital for 
medical reasons, for any length of time. Presentation and care within an emergency department does not necessarily constitute an SAE. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization, it is an SAE. 
8.4.6 SAE  Reporting Requirements to the Sponsor  
The procedure for reporting SAEs, regardless of causal relationship , is as fo llows: 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 33 of 43  • Within 24 hours of the Investigator’s knowledge of an SAE, the site must notify the Sponsor  
by phone call to their site monitor, medical monitor or other Sponsor representative. They 
should also immediately complete the AE eCRF and select “Serious”. 
• This initial reporting of an SAE should contain as much information as is available to the 
Investigator. Submission of the SAE via the EDC should not be delayed in order to collect 
additional information to complete the form.  
• Follow- up SAE reports may be generated in cases in which additional information becomes 
available. Hospital records, autopsy reports, and other documents may become available and 
scanned copies can be prov ided to the Sponsor  when applicable. The follow -up SAE report 
should describe whether the event has resolved or continues, if and how it was treated, whether the blind was broken or not, and whether the subject  continued or withdrew from 
study participation.  
• The Sponsor  will distribute completed SAE forms, which may be used to notify the IRB 
when applicable, via a secure internet -based document depository. 
• The Investigator should notify the IRB of Serious Adverse Events occurring at the site and 
other adverse reports received from the Sponsor in accordance with local procedures.  
The Investigator must take all therapeutic measures necessary for resolution of the SAE. Any 
medications necessary for treatment of the SAE must be recorded onto the concomitant medication section  of the subject ’s eCRF.  
8.5 Suspected Unexpected Serious Adverse Reactions (SUSARs)  
A SUSAR carries specific and time- based reporting requirements for the Sponsor of a clinical 
trial. Thus, after an Investigator reports an SAE, the FDA expects the Sponsor will  determine 
whether it meets the definition of a SUSAR.  
A SUSAR is defined according to 3 criteria: 
1. The AE is deemed a “suspected adverse reaction” if there is a reasonable possibility that the 
study drug caused the AE. A “reasonable possibility” means ther e is evidence to suggest a 
causal relationship between the drug and adverse event. 
2. The AE is “Serious” if it meets the definition of an SAE provided in section 8.4.5 
3. The AE is deemed “unexpected” if it is not listed in the Investigator’s Brochure (IB) or if in the IB, has not been reported at the severity observed. 
In cases where the Sponsor deems a SUSAR has occurred, it must file an IND Safety Report with the FDA. FPHU  will require the assistance and cooperation of the Investigator and staff to 
provide accurate and complete information on the subject and observed SAE so that reporting requirements to the FDA can be met.  
8.5.1 Reporting SUSARs to the FDA: IND Safety Reports  
IND safety reports are used to submit reports of SUSARs to the FDA. There are 2 types of reports:  
• A “15 -day report” is used when the reported SAE is a  SUSAR and requires that as much 
information as is available to the investigator and the sponsor, be submitted to the FDA in on 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 34 of 43  the appropriate form. For US trials, the appropriate form is the FDA Form 3500A also 
commonly known as a “MedWatch” form. 
• A “7 -day report” is used when the SUSAR is considered to be fatal or life- threatening.  
The 7 -day and 15- day timelines begin the day that the Investigator learns of the event and are 
counted in calendar days – not business days. Therefore, it is important that the investigator 
carefully follow the reporting requirements described in section  8.4.6. 
8.6 Clinical Laboratory Abnormalities and Other Abnormal Assessments 
Laboratory abnormalities are usually not recorded as AEs  unless considered to be clinically 
significant by the site clinician . An abnormal laboratory result will be considered an AE if it 
induces clinical signs or symptoms, if the abnormality is of a degree that requires active management (e.g. discontinuation of the study drug, dose modification) or when the event is requiring trea tment or other therapeutic intervention (e.g. iron supplements, blood transfusion, 
etc.).  
The Investigator will evaluate the relationship of any significantly abnormal result to protocol treatment and clinical condition, if possible. All clinically signifi cant abnormal laboratory results 
will be followed until they return to normal or become stabilized . 
8.7 Handling of Overdose  
An overdose is defined as any dose greater than the highest daily dose included in this document. 
Any overdose must be recorded. If the  overdose is associated with an AE, that AE must be  
recorded , assessed for seriousness, and reported as an SAE. 
9 STATISTICAL METHODS  
9.1 General Considerations  
This study is intended to support a Phase 3 registrational  trial in this patient population by 
providing information on the treatment effect on an unambiguous indicator of antiviral activity, i.e., the time to viral clearance, as well as to estimate the treatment effect on a number of important clinical and symptomatic disease correlates . Proof of concept will be established by a 
significant treatment effect on the primary endpoint of time to viral clearance . Based upon 
available data, a two -arm study of approximately 50 total subjects will be sufficient to provid e 
reasonable assurance that the endpoints chosen for a confirmatory trial will elucidate treatment differences between favipiravir  + SOC  and SOC . Statistical significance testing will be used to 
assess the relative strength of evidence of the primary and s econdary endpoints ; given that this 
trial is intended as a proof of concept, a two -sided alpha -level of 0.10 will be used for 
significance testing . 
It is important to ensure that reasonable certainty is achieved in the conclusions reached for key secondary  endpoints, therefore key secondary endpoints will be adjusted for multiple statistical 
testing through a gatekeeping hierarchical methodology, as follows : Statistical significance for 
the first secondary endpoint, according to the order outlined in the endpoints section of this 
protocol, will be declared only if the primary endpoint has previously reached statistical significance. Subsequent endpoint analyses in the order presented will be declared significant 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 35 of 43  only if the previous endpoint in order has rea ched statistical significance. All analyses of 
secondary endpoints will also be conducted at the two- sided alpha -level of 0.10. The order of 
secondary endpoint analysis will be the following: the study -specific 6 -point ordinal scale; time 
to clinical recov ery; reduction in disease symptoms; reduction in oxygen/ventilation 
requirements.  
Tabulations will be produced for appropriate demographic, baseline, efficacy, pharmacokinetic, 
and safety parameters. For categorical variables, summary tabulations of the number and percentage of subjects within each category (with a category for missing data) of the parameter will be presented. For continuous variables, the number of subjects, mean, median, standard deviation (SD), minimum, and maximum values will be present ed, as well as 2 -sided 95% 
confidence intervals (CIs). Summaries of categorical data will include counts and percentages, along with 2- sided 95% CIs. Kaplan Meier methods will be used to summarize the time -to-event 
endpoints, including 25th, 50th (median), and 75th percentiles with associated 2- sided 95% CIs, 
as well as percentage of events and censored observations. 
Complete details of all statistical analyses, including methods for handling missing data, will be 
included in a formal statistical analysis p lan (SAP), to be completed as soon as possible after 
study initiation.  
9.2 Sample size justification  
Approximately 50 subjects will be enrolled. The primary endpoint analysis will consist of a log -
rank test of the difference in treatment groups in the time to viral clearance. Based on a recent publication: 
(https://www.sciencedirect.com/science/article/pii/S2095809920300631?via%3Dihub) 
it is assumed that the median time to clearance for favipiravir would be approximately 4 days, 
and the median time for SOC  would likely be approximately 11 days; this latter estimate may in 
fact be conservative since SOC  is not as likely to reduce viral load as well as the control in  the 
above referenced study . Using  two-sided alpha of 0.10 and power of 90% (appropriate for a trial 
to be used as the justification for a confirmatory, fully -powered blinded and randomized Phase 3 
study), and a fixed per -subject observation period of 15 days, an approximate sample size of 25 
subjects per arm (total size of 50) would be required.  
9.3 Demographic and Baseline Characteristics  
Summary statistics will be provided per treatment group for demographic (e .g., age, height, 
weight, body mass index [BMI] , race, gender) and other initial subject characteristics ( e.g., 
medical history, concomitant diseases) will be provided per treatment group and for the total group. The ITT population will be used for the summaries. 
9.4 Analysis Populations 
The following analysis populations will be defined for the study: 
• Intent- to-treat (ITT) population – All subjects randomized to treatment. Subjects in the ITT 
population will be analyzed based on the treatment to which they were randomized, 
irrespective of what treatment th ey actually received.  This population was selected for the 
analysis of the primary and secondary endpoints in order to maintain the benefits of 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 36 of 43  randomization and avoid the potential bias associated with the non- random loss of the 
participant.  
• Safety popula tion – All ITT subjects who received either favipiravir + SOC, or SOC alone . 
Subjects in the safety population will be analyzed based on the actual treatment they 
received, irrespective of the treatment to which they were randomized. It is anticipated that  
the safety population will be the same as the ITT population. 
• Modified intent -to-treat (MITT) – All subjects of the safety population that have an 
assessment of viral shedding after randomization and are confirmed COVID -19 positive. 
Subjects in the MITT population will be analyzed based on the treatment to which they were randomized, irrespective of what treatment they actually received. 
• Per protocol (PP) population – All MITT subjects who adhere to relevant study procedures 
and have an outcome assessment.  Further specific details defining the analyses to be 
performed on this population will be described in the SAP. 
• PK population (PK) – All subjects in the safety population that have at least one result that 
can be used in the PK summaries.  
9.5 Stratification, Subgroup Analysis and Pooled Analysis 
The stratification factor s used in randomization, critical v. severe v. mild/moderate disease as 
defined above based on supplemental oxygen requirements, SpO2 status etc., will be accounted for in the efficacy analyses . The stratification factor may be deleted from the statistical model if 
the interaction is not significant at the 0.10 level. Efficacy data will be pooled across study sites for analysis, after visual inspection of summary results reveals similarity acros s study sites. 
Efficacy results may also be summarized within each randomization stratum for exploratory purposes. 
9.6 Efficacy  Endpoint Analysis  
The primary endpoint of time to viral clearance will be analyzed with the log -rank test for 
treatment difference and summarized using the Kaplan- Meier methodology as noted above. Viral 
load results from day of discharge as available will also be included in the analysis of viral clearance.  
The key secondary endpoint of status of c linical recovery as measured by the s tudy- specific 6-
point ordinal scale at Day 15  will be analyzed using ordinal categorical data methods, since it is 
unlikely that linear differences exist between the elements of the scale (for example, a 1 -point 
difference in magnitude may not apply to eac h increment on the scale). As an exploratory 
analysis, sequential binary analysis will be performed, based on successive classification of a subject into categories of less than or greater/equal to each ordinal item on the scale. Longitudinal analysis of the 6-point scale over time on study will also be performed to 
investigate temporal patterns of improvement.  
Time to event endpoints will be analyzed using similar methods as used for the primary endpoint; these will include time to: clinical recovery; defe rvescence; cough mild or absent; 
dyspnea mild or absent; SARS -CoV-2 RT- PCR negative in upper respiratory tract . 
Categorical endpoints will be analyzed using categorical data analysis methods; continuous data will be analyzed using analysis of variance with  treatment and strata as factors.  
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 37 of 43  Missing efficacy data in a trial of hospitalized patients is generally unlikely, and great care will 
be taken at each study site to ensure that all outcome assessments are obtained as planned in this 
protocol. However, as treatment of COVID -19 subjects evolves, it is clear some subjects will be 
discharged from the hospital prior to Day 15.  Subjects are asked to return for follow up visits on Days 29, 45 and 60.  This requirement is presenting challenges for subjects and in order to 
ensure that in cases where the subject does not return for their follow up visits, an additional swabbing has been added on the day of hospital discharge (See Section 7.7).  Should missing data occur for the primary endpoint, time to viral cleara nce, such patients will be included in the 
log-rank analysis as censored observations. Missing clinical outcome data will be evaluated 
using a variety of methods, including multiple imputation, worst -value assignment, and other 
methods, to be completely outlined in the statistical analysis plan.  
9.7 Safety Analysis 
The original exact terms in the electronic data capture (EDC) system used by Investigators to identify AEs other than symptoms of COVID -19 will be fully described and coded according to 
the Medical D ictionary for Regulatory Activities (MedDRA). Treatment- emergent AEs will be 
defined as those occurring coincident with start of treatment and through Day 60. TEAEs will be 
summarized overall and by treatment group and by MedDRA body organ system and prefe rred 
term, severity, relatedness, and seriousness. 
An overall summary of TEAEs will be presented by treatment, with subject counts and 
percentages of subjects with the event. This summary will include subjects with any TE AE, any 
treatment -related TEAE, any  serious TEAE, any treatment- related serious TEAE, TEAEs 
leading to study infusion discontinuation, treatment -related TEAEs leading to study infusion 
discontinuation, TEAEs leading to death, and treatment -related TEAEs leading to death. The 
difference in proportions between treatment groups in each of these categories will be calculated.  
Summaries of changes over time in laboratory parameters, as well as counts and percentages of laboratory parameters that are Low, Normal, and High compared to the reference ranges will be 
presented by treatment at each visit and time point. Shift tables will be presented for laboratory parameters with defined severity  grades.  
10 RECORDING AND COLLECTION OF DATA  
10.1 Case Report Form  
The Investigator or designee will record all data collected on the electronic Case Report Form 
(eCRF) provided for that purpose. The site will be suitably trained on the use of the eCRF and 
appropriate site personnel will be provided electronic signatures. 
All site entries will be made in a secured web site  and the Principal Investigator will review the 
record for completeness . Upon completion of the review, the PI will sign electronically in the 
signature page of the e CRF.  
The Investigator or designee will make necessary eCRF corrections. The investigat or must 
authorize the corrections to the entered data on eCRF.  
Specific instructions on use of the EDC system and guidelines for data entry and correction will 
be provided to the sites. 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 38 of 43  10.2 Study Files and Subject  Source Documents  
Subject  confidentiality is strictly held in trust by the participating investigators, research staff, 
the Sponsor  and their designees . This confidentiality is extended to cover testing of biological 
samples  in addition to the clinical information relating to subj ects. Authorized representatives of 
the Sponsor  may inspect all documents and records required to be maintained by the 
Investigator, including but not limited to, medical records (office, clinic or hospital) and 
pharmacy records for the subject s in this study. Any data, specimens, forms, reports, and other 
records that leave the site will be identified only by a subject identification number to maintain 
confidentiality . 
The Investigator must maintain adequate and accurate records to enable the conduct of th e study 
to be fully documented and the study data to be subsequently verified. These documents include Investigators’ Study Files and original subject clinical source documents generated at the study 
site. The term “original” means the first recording of the data.  
The Investigator will ensure the site master files  are maintained, including the study protocol and 
its amendments, IRB  and regulatory approvals with associated correspondence, informed 
consents, study drug records, staff curriculum vitae, all correspondence, and other appropriate documents. 
Subject  clinical source documents may include, but are not limited to, subject  hospital/clinic 
records, physicians’ and nurses’  notes, appointment books, laboratory reports, ECGs, 
radiographs, and consultant le tters. The Investigator must assure that all original source 
documents are available t o support monitoring activities. 
10.3 Monitoring  
Due to the restrictions imposed on clinical and hospital visits by the COVID -19 pandemic, all 
monitoring of this study will be  conducted remotely. Monitors will work with the Study 
Coordinator at each site to determine times for “joint” remote monitoring – meaning that the 
monitor and the SC will review data together over the telephone.  
Remote monitoring will be conducted according to the applicable ICH and GCP guidelines to 
ensure protocol adherence, quality of data, drug accountability, compliance with regulatory 
requirements and continued adequacy of the investigational site and its facilities. T he 
Investigator will cooperate in the monitoring process by ensuring the availability of the eCRFs, source documents and other necessary documents at the time of remote monitoring and by 
prompt attention to any matters brought to his/her attention by the monitor.  
10.4 Audit  
ICH guidelines for  GCP require independent inspection of clinical program activities.  Such 
inspections may be performed at any time  - before, during and/or after the study. The 
Investigator and study staff are responsible for maintaining the site master file containing all  
study- related regulatory documentation as outlined by the Sponsor  that will be suitable for 
inspection at any time by the Sponsor, its designees, and/or regulatory agencies. The  Investigator 
understands and agrees to give access to the necessary documentation and files. 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 39 of 43  10.5 Retention of Data  
All records connected with this clinical study will be retained for at least two years following the 
date of an approved marketing application [21 CFR 312.62(c)] ; or at least three years from the 
formal discontinuation of favipiravir development; or seven  years from the end of the study, 
whichever is longer . All local laws regarding retention of records must also be followed.  Study 
sites are required to retain all records until written notification allowing destruction is received from  the Sponsor. 
11 ETHICS 
11.1 Ethics Committee  
A properly constituted, valid IRB /IEC  must review the treatment plan  and procedure s, the 
Investigator’s in formed consent document, and related subject  information . It is the 
responsibility of the Investigator to ensure that all aspects of institutional review are conducted in accordance with current regulations governing the jurisdiction where the study is conducted. The 
Sponsor (or designee) must receive a letter documenting IRB /IEC  approval that specifically 
identifies the title of the treatment plan , subject information sheet, and ICF . 
11.2 Subject Information and Consent  
It is the responsibility of the Investiga tor to ensure that written informed consent is obtained 
from the subject  or legal representative before any activity or procedure is undertaken that is not 
part of routine care. The informed consent must comply with local regulations. 
The background of the study, the procedures, the potential benefits and risks of the treatment , 
and the fact th at treatment is voluntary for the subject must be explained to the subject  or legal 
representative. The subject  or representative must be given s ufficient time to consider whether  
to consider whether or not to participate  in the study . A copy of the ICF, signed and dated by the 
subject/representative and the Investigator (or designee), must be given to the 
subject/representative. Confirmation of a  subject’s informed consent must also be documented in 
the subject’s medical record prior to any treatment with favipiravir . 
Each consent form should contain an authorization allowing the Investigator and the Sponsor (or 
designee) to use and disclose prote cted health information (PHI) ( i.e., subject -identifiable health 
information) in compliance with local law. The signed consent form will be retained with the treatment  records.  
12 GENERAL  CONSIDERATIONS  
12.1 Discontinuation of the Study  
The Sponsor reserves the right to discontinue the study at any time for any reason.  
12.2 Use of Information and Publication 
All information concerning favipiravir, Sponsor operations, patent applications, formulas, 
manufacturing processes, basic scientific data, formulatio n, and other information supplied by 
the Sponsor to the Investigator and not previously published is considered confidential and 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 40 of 43  remains the sole property of the Sponsor. The Investigator agrees to use this information only to 
treat this patient and will n ot use it for other purposes without written consent of the Sponsor. 
The information obtained in this study will be used by the Sponsor in connection with the 
continued development and, if approved, commercialization of favipiravir. Thus, Sponsor may discl ose such information as required to other clinical Investigators, contractors, and government 
regulatory agencies.  
Publication or other public presentation of results from this study and related information is subject to the provisions of the Clinical Trial Agreement between Sponsor and the Study Site. 
 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.   Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
 
Confidential and Proprietary  Page 41 of 43  13 SCHEDULE OF ASSESSME NTS  
 
  ASSESSMENT  HOSPITALIZED  FOLLOW UP  
Outpatient or Hospitalized  
 DAY 1  
PRE -DOSE  DAY 1 
POST -DOSE  DAY 2  DAY 3  DAY 8  Day 11  DAY 14  DAY 15  
(-1 to + up 
to 2 days ) DAY 29 ±  
2 days  DAYS 45 
and 60 ±  
2 days8 
Informed Consent  X          
Medical/Surgical History  X          
Physical Exam 10 X                  
Limited Physical Exam3 
  X X X X X X X X X 
Concomitant Medications 
Review12 X  X X X X X X X X 
Review of Entry Criteria  X          
Vital Signs (BP, HR, Temp, 
Resp)3 X X X X X X X X X X 
Clinical Laboratory 
Exams1,2.,9  X   X X X  X X  
Blood for antibodies to 
SARS -CoV -2 X       X X  
Blood for PK Sampling X4 X4 X5  X6 X5 X6 X5    
SpO2 by Finger Sensor3  X X X X X X X X X X 
Urine  or Blood Pregnancy  
Test  X          
Nasopharyngeal and 
Oropharyngeal Swabs for 
Viral RNA, PCR and 
TCID 50 X   X11 X11 X11  X X  
Clinical Status – 6-point 
Ordinal Scale 3 X  X X X X  X X X 
National Early Warning 
Score (NEWS2)3 X  X X X X  X X X 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.  Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
Confidential and Proprietary                                                                                    Page 42 of 43   
1. Hematology, Chemistry ( See Section 8.4). 
2. May use results of labs taken at the hospital as part of SOC if done no more than 24 hours prior . 
3. To be measured every day while hos pitalized  and at each clinic visit after hospital discharge through Day 60  
a. Vital signs   
b. Clinical Status 6- point scale   
c. NEWS 2 
d. ECOG Performance status  
e. Study- specific symptom status   
f. Adverse Events   
g. SpO2  
h. Limited PE  (heart and lungs)  
4. PK on Day 1 prior to favipiravir dosing and between 45 to 75 minutes post -first dose . 
5. PK trough samples to be taken approximately 30 minutes prior to any dose.  
6. PK p eak samples to be taken between 45 to 75 minutes post -dose 
7. Maintenance dose for CP score A is 800  mg BID . 
8. Days 45  and 60 may be completed in the hospital, outpatient clinic , or by phone  
9. Subjects will undergo 9 planned venipunctures . 
10. To be completed by PI or designe e 
11. Days 3, 8, 11 Nasopharyngeal and Oropharyngeal Swabs for Viral RNA, PCR and TCID 50 may be done +/ - 1 day from their scheduled day. Swabs will also 
be obtained on day of discharge from hospital if discharge occurs before Day 15.  
12. To be checked throughout hospitalization and at clinic visits and changes only recorded as applicable.  
  DAY 1  
PRE -DOSE  DAY 1 
POST -DOSE  DAY 2  DAY 3  DAY 8  Day 11  DAY 14  DAY 15  
(-1 to + up 
to 2 days)  DAY 29 ±  
2 days  DAYS 45 
and 60 ±  
2 days8 
ECOG Performance Status3 X  X X X X X X X X 
Study Specific Symptom 
Status3 X  X X X X X X X X 
Randomization  X          
Investigational Product 
Dosing   Favipiravir Dosing Days 1 -14 
(1800  mg BID on Day 1000  mg BID Days 2 -14)7    
Solicitation of Treatment -
Emergent Adverse Events3  X X X X X X X X X 
Release from the Study             X 
FUJIFILM Pharmaceuticals  U.S.A. , Inc.   Version 6.0  
Protocol FAVI- COV -US201  15July2020 
 
 
Confidential and Proprietary  Page 43 of 43  Appendix A: Subject Status Scales  
  1. ECOG Performance Status  
 
GRADE  ECOG PERFORMANCE STATUS  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light housework , office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities; up 
and about mor e than 50% of waking hours  
3 Capable of only limited selfcare; confined to bed or chair more than 50% of waking 
hours  
4 Completely disabled; cannot carry on any selfcare; totally confined to bed or chair  
5 Dead  
 
*Oken M, Creech R, Tormey  D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol.  1982;5:649 -
655. 
  2. Study Specific Symptom Status  Scale 
 
Symptom  Present? Y/N  Severity:  
Mild, Moderate, Severe  
Feeling Feverish    
Dyspnea    
Cough    
Use of Antibiotic    
  